Employees: 14,846
Size China Traditional Chinese Medicine (0570.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $716M, the 662nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$1.13 on 18 Nov 2026.
Performance Over six months the shares fell 30.7%, against -10.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue fell 15.8% over the last twelve months (peer median +3.9%); the operating margin is 0.0% (peer median 9.7%).
Valuation It trades at 0.3× enterprise value to sales against a peer median of 2.1× (cheapest of 19).
Capital Return on invested capital runs 7.2 points below its cost of capital (7.2% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$14.2B | HK$16.0B | HK$17.9B | HK$20.0B | HK$16.6B |
| Revenue growth | — | -11% | -11% | +20% | — |
| Gross profit | HK$6.73B | HK$7.69B | HK$8.52B | HK$10.2B | HK$8.37B |
| EBITDA | HK$1.25B | HK$1.58B | HK$1.95B | HK$2.50B | HK$2.47B |
| Net income | -HK$1.14B | -HK$371M | HK$58.6M | HK$1.42B | HK$889M |
| Free cash flow | HK$1.63B | HK$1.67B | HK$2.84B | HK$1.25B | HK$43.6M |
| Capital expenditure | HK$296M | HK$352M | HK$555M | HK$540M | HK$613M |
| Total debt | n/a | HK$2.78B | HK$4.27B | HK$5.68B | HK$5.66B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0570.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.8% | -8.4% | 10th highest of 21 |
| 6-month return | -30.7% | -10.1% | 7th lowest of 21 |
| Distance from 52-week high | -52.9% | -34.0% | 4th lowest of 21 |
| Revenue growth (TTM) | -15.8% | +3.9% | 3rd lowest of 19 |
| Operating margin | 0.0% | 9.7% | 4th lowest of 19 |
| EV / Sales | 0.3× | 2.1× | cheapest of 19 |
| ROIC minus cost of capital | -7.2 pp | +1.5 pp | 2nd lowest of 17 |
| EV / EBITDA | 3.8× | 4.7× | 3rd cheapest of 5 |
| Net debt / EBITDA | -3.0× | -1.2× | least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | 0.3× | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 0.8× | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 2.6× | -4.8% | +6.4% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 3.9× | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | 16.1× | 42.7% | -0.9% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 3.8× | 5.9% | +11.3% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | 0.6× | 4.0% | +5.3% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 1.1× | -11.8% | +1.9% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 1.8× | -2.0% | +26.1% |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 0.5× | -1.6% | -1.8% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 2.5× | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | 1.4× | -2.1% | 0.0% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | 5.3× | 9.4% | -1.4% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | 2.5× | 13.5% | -0.2% |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | 1.6× | -8.3% | -2.8% |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 1.7× | n/a | n/a |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 0.9× | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 6.7× | 31.9% | +19.8% |